Phase III OlympiAD trial overall survival results for Lynparza in metastatic breast cancer.- AstraZeneca + Merck Inc.
AstraZeneca and Merck presented data from the Phase III OlympiAD trial showing the final overall survival (OS) results for Lynparza in metastatic breast cancer at the American Association for Cancer Research (AACR) Annual Meeting in Chicago from April 14-18.
The trial compared Lynparza with chemotherapy (physician�s choice of capecitabine, eribulin or vinorelbine) for patients with germline BRCA-mutated (gBRCAm), HER2-negative metastatic breast cancer and met its primary endpoint of progression-free survival (PFS). Results at AACR include updated findings from the secondary endpoint of overall survival (OS).
While the trial was not powered to demonstrate a statistically significant difference, the median OS was 19.3 months in patients treated with Lynparza and 17.1 months for patients treated with chemotherapy (HR 0.90, 95% CI 0.66-1.23; p=0.513). At the final OS data cutoff (64% maturity), 13 percent of patients remained on Lynparza and no patients remained on chemotherapy.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.